Additionally, the expression levels of these two proteins were significantly correlated with advanced WHO stage and low KPS scores, suggesting that CCL20 and CCR6 expression might be of clinical relevance in the aggressiveness of gliomas [47]. The gene discussed is CCL20; the disease is central nervous system cancer.